AI may predict heart risk in cancer patients

NCT ID NCT07191730

Recruiting now Knowledge-focused Sponsor: University Hospital, Caen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop a machine learning tool to predict heart damage in 600 cancer patients receiving certain chemotherapy drugs (anthracyclines or HER2-targeted therapies). Researchers will collect data over one year to see who develops heart problems. The goal is to create a more accurate risk score than current methods, helping doctors identify high-risk patients early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a better way to identify which cancer patients are at high risk of heart problems from their treatment, allowing for closer monitoring or preventive measures.
What could go wrong: This is an observational study, not a treatment trial. The machine learning model may not prove accurate enough for widespread use, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Cardiotoxicity heart failure neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS CARDIOTOXICITY HEART FAILURE NEOPLASMS

Contacts and locations

Locations

CHU de Caen
RECRUITING

Caen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.